MAHWAH, N.J., May 7, 2015 /PRNewswire/ -- PAION, Inc., a wholly
owned subsidiary of PAION AG, is pleased to announce today that
David Bernstein, M.D. has agreed to
become PAION's Medical Advisor. In this role, Dr. Bernstein will
participate in building the company's U.S. relationships with the
academic community, regulators, associations and industry. He will
also play an active role in the growth of the company's value
proposition, with a special focus on the U.S.
Dr. Bernstein will also be heavily involved in steering PAION's
efforts with its recently established medical advisory board, which
consists of U.S. national thought leaders in the field of
gastroenterology who are also participating in our phase 3
program.
Dr Wolfgang Sohngen, M.D., Ph.D.,
chief executive officer of PAION AG, said, "I'm thrilled to
continue to work with Dr. Bernstein to bring Remimazolam to a
commercial success. David's contributions in helping us put
together our medical advisory board last year were significant. We
hope this will be a long and rewarding relationship with one of the
most respected physicians in the field of
gastroenterology."
Greg Papaz, president and chief
executive officer of PAION, Inc., added: "It is a
privilege to have a physician of David's prestige as a director of
PAION Inc. I am confident he will help us achieve our goals in the
U.S."
Dr. Bernstein is currently chief of hepatology for both North
Shore University Hospital and Long Island Jewish Hospital, as well
as the director of the Center for Liver Diseases for the North
Shore LIJ Health System and a professor of medicine at the Hofstra
North Shore LIJ School of Medicine. Dr. Bernstein has authored over
100 publications, 10 book chapters, and has been the principle
investigator in more than 100 clinical trials. His work has been
published in such prestigious journals as the New England Journal
of Medicine and The Lancet.
Dr. Bernstein has held elective offices in many national and
international societies. He is the current president of the Bockus
International Society of Gastroenterology and a former president of
the New York Gastrointestinal Association. He served for six years
as the American College of Gastroenterology governor for
Long Island and was a member of
numerous other medical committees. Currently, he is a fellow of the
American Association for the Study of Liver Diseases, the American
College of Gastroenterology and the American College of Physicians.
He also serves as a special consultant to the New York State Department of Health. He has
received numerous awards recognizing his contributions, in
academia, as a clinician, and in the field of public health.
"I am delighted to be involved with Remimazolam, a welcome
alternative for which gastroenterologists have waited many years. I
look forward to the challenges ahead and I am confident that we
will see the potential of Remimazolam fully realized in
the United States," commented
Dr. Bernstein.
PAION will be present at the Digestive Disease week (DDW 2015)
between May 17-19, 2015 in
Washington, U.S. and will be
available for discussions at booth 1865 in the exhibition hall.
About Remimazolam
Remimazolam is an innovative
ultra-short-acting general sedative/anesthetic. As a result of its
short duration of action and good controllability, it has a
preferable efficacy and safety profile relative to other currently
marketed anesthesia compounds. Remimazolam's rapid offset is a
consequence of its metabolism by tissue esterase enzymes that are
widely distributed throughout the body. Remimazolam has potential
in three indications:
- Procedural sedation (Lead indication U.S.)
- General anesthesia (Lead indication EU, Japan)
- ICU sedation (Phase 2 Japan)
Remimazolam is available for licensing outside China, Russia
(CIS) Turkey, MENA Region,
South Korea and Canada, where the compound is partnered with
Yichang Humanwell, R-Pharm, TR-Pharm, Hana
Pharm and Pendopharm.
About PAION
PAION AG is a publicly-listed Specialty
Pharma Company headquartered in Aachen, Germany with further sites in Cambridge, UK and New Jersey, US. The company has a track record
of developing hospital-based treatments for which there is
substantial unmet medical need. PAION's strategy is to participate
in the commercialization of Remimazolam and extend its business
with a focus on anesthesia/critical care products. Remimazolam is
the building block for its future marketing activities.
For more information please visit www.paion.com
PAION Corporate Contact
Greg
Papaz
President and CEO
PAION, Inc.
201-512-8850
g.papaz@paion.com
Media Contact
Matt Middleman, M.D.
Russo Partners
(212) 845-4272
matt.middleman@russopartnersllc.com
PAION AG Contact
Ralf
Penner
Director Investor Relations / Public Relations
PAION AG
Martinstrasse 10-12
52062 Aachen – Germany
Phone: +49 241 4453-152
E-mail: r.penner@paion.com
www.paion.com
Investor Relations Support in the US
The Trout
Group
Thomas Hoffman
+1 646 378 2931 Direct
thoffmann@troutgroup.com
www.troutgroup.com
Disclaimer:
This release contains certain forward-looking statements
concerning the future business of PAION, Inc. These forward-looking
statements contained herein are based on the current expectations,
estimates and projections of PAION, Inc's management as of the date
of this release. They are subject to a number of assumptions and
involve known and unknown risks, uncertainties and other factors.
Should actual conditions differ from the Company's assumptions,
actual results and actions may differ materially from any future
results and developments expressed or implied by such
forward-looking statements. Considering the risks, uncertainties
and other factors involved, recipients should not rely unreasonably
upon these forward-looking statements. PAION, Inc. has no
obligation to periodically update any such forward-looking
statements to reflect future events or developments.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/david-bernstein-md-joins-paion-as-medical-advisor--non-executive-director-of-paion-inc-300079464.html
SOURCE PAION, Inc.